Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma



Summary

Combining MCL-1 inhibition with CD37-directed CAR T-cell therapy shows promise for treating T-cell lymphoma. MCL-1 is a protein crucial for T-cell lymphoma survival, and its inhibition sensitizes cancer cells to CAR T-cell killing. CD37 is a protein highly expressed on T-cell lymphomas, making it an ideal target for CAR T-cells. Preclinical studies demonstrate that MCL-1 inhibitors enhance the efficacy of CD37 CAR T-cells, leading to increased cancer cell death and improved tumor control. This combination strategy could offer a more effective treatment approach for T-cell lymphomas compared to either therapy alone.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!